You are here

NDA Submitted for Genasense in Advanced Melanoma

BERKELEY HEIGHTS, NJ – December 9, 2003 —Genta Incorporated (Nasdaq: GNTA) announced that the Company completed the submission of its New Drug Application (NDA) for Genasense™ (oblimersen sodium) used in combination with dacarbazine for the treatment of patients with advanced malignant melanoma on December 8, 2003. The application process, which began in the 3rd quarter of this year, was submitted under the Fast Track program of the U.S. Food and Drug Administration (FDA) that is designed to expedite review of new drugs that address important unmet medical needs. The Company has requested designation of the Genasense NDA for Priority Review. Applications that are granted priority review are usually targeted for action by the FDA within six months from the date the submission is completed.

About Genasense
Genasense inhibits production of Bcl-2, a protein made by cancer cells that is thought to block chemotherapy-induced cell death. By reducing the amount of Bcl-2 in cancer cells, Genasense may enhance the effectiveness of current anticancer treatments. Based on preclinical and clinical studies that demonstrate anti-tumor effects in a broad range of cancers, Genta is studying Genasense in multiple, late-stage randomized and non-randomized clinical trials, including multiple myeloma, chronic lymphocytic leukemia, non-small cell lung cancer, small cell lung cancer, and prostate cancer.

About Malignant Melanoma
Malignant melanoma is the most deadly form of skin cancer. The incidence of this disease is increasing by approximately 4% annually in the US. In 2003, the American Cancer Society estimates more than 54,000 cases of malignant melanoma will have been diagnosed. Melanoma is the number one cause of cancer death in women aged 25 to 29.

Source: Genta Incorporated

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Acasti reports disappointing results for a second Omega-3-based drug
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks